Cancer despite immunosurveillance: immunoselection and immunosubversion
The DOI matches its Crossref record; 127 of the 127 references it cites were found in a registry or an index.
Abstract
Numerous innate and adaptive immune effector cells and molecules participate in the recognition and destruction of cancer cells, a process that is known as cancer immunosurveillance. But cancer cells avoid such immunosurveillance through the outgrowth of poorly immunogenic tumour-cell variants (immunoselection) and through subversion of the immune system (immunosubversion). At the early stages of carcinogenesis, cell-intrinsic barriers to tumour development seem to be associated with stimulation of an active antitumour immune response, whereas overt tumour development seems to correlate with changes in the immunogenic properties of tumour cells. The permanent success of treatments for cancer might depend on using immunogenic chemotherapy to re-establish antitumour immune responses.
Overview
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
Claims other papers make about this one
Each is checked against this paper’s own text: does it say what the citing paper says it does?
In the citing paper
“Cancers must escape from immunosurveillance to advance to a clinically detectable state, meaning that they either are passively selected to ''hide'' from immune recognition (immunoselection) or actively suppress immune effectors (immunosubversion).249”
From Meta-hallmarks of aging and cancer (2023) · cites this paper as [249]
Citations
Cites
Hanahan, D., & Weinberg, R. A. (2000) · Cell · doi:10.1016/s0092-8674(00)81683-9 · Cited by 29,219
Bettelli, E., Carrier, Y., Gao, W., Korn, T., Strom, T. B., Oukka, M., Weiner, H. L., & Kuchroo, V. K. (2006) · Nature · doi:10.1038/nature04753 · Cited by 6,992 · cited 1×
“By contrast, it is thought that TGFβ can also have immunostimulatory effects (in particular, on specific T H -cell subset”
BackgroundCuriel, T. J., Coukos, G., Zou, L., Alvarez, X., Cheng, P., Mottram, P., Evdemon-Hogan, M., Conejo-Garcia, J. R., Zhang, L., Burow, M., et al. (2004) · Nature Medicine · doi:10.1038/nm1093 · Cited by 5,151
The Pathophysiology of Mitochondrial Cell Death
Green, D. R., & Kroemer, G. (2004) · Science · doi:10.1126/science.1099320 · Cited by 3,418
Sakaguchi, S. (2004) · Annual Review of Immunology · doi:10.1146/annurev.immunol.21.120601.141122 · Cited by 3,306
The Three Es of Cancer Immunoediting
Dunn, G. P., Old, L. J., & Schreiber, R. D. (2004) · Annual Review of Immunology · doi:10.1146/annurev.immunol.22.012703.104803 · Cited by 3,072
The Immunobiology of Cancer Immunosurveillance and Immunoediting
Dunn, G. P., Old, L. J., & Schreiber, R. D. (2004) · Immunity · doi:10.1016/j.immuni.2004.07.017 · Cited by 3,032
DNA damage response as a candidate anti-cancer barrier in early human tumorigenesis
Bartkova, J., Hořejší, Z., Koed, K., Krämer, A., Tort, F., Zieger, K., Guldberg, P., Sehested, M., Nesland, J. M., Lukas, C., et al. (2005) · Nature · doi:10.1038/nature03482 · Cited by 2,688
Uyttenhove, C., Pilotte, L., Théate, I., Stroobant, V., Colau, D., Parmentier, N., Boon, T., & Van den Eynde, B. J. (2003) · Nature Medicine · doi:10.1038/nm934 · Cited by 2,305 · cited 1×
“More importantly, tryptophan degradation by indoleamine 2,3-dioxygenase ( IDO ), which is constitutively expressed by human tumours (particularly by prostate, colon and pancreatic carcinomas, but also by interdigitating DCs), promotes resistance to immune-mediated rejection of the tumour cell”
BackgroundImmunosuppressive networks in the tumour environment and their therapeutic relevance
Zou, W. (2005) · Nature Reviews Cancer · doi:10.1038/nrc1586 · Cited by 2,057
Cited by
Items 501–600 of 1,000
Strioga, M. M., Darinskas, A., Pašukonienė, V., Mlynska, A., Ostapenko, E., & Schijns, V. E. C. J. (2014) · Vaccine · doi:10.1016/j.vaccine.2014.05.006 · Cited by 39
Karasar, P., & Esendağlı, G. (2014) · Breast Cancer Research and Treatment · doi:10.1007/s10549-014-2984-9 · Cited by 40
“T cells were associated with accumulation Tregs which could also proliferate in the PDL1? tumor microenvironment [36].”
BackgroundInfluentialClairambault, J. (2009) · Mathematical Modelling of Natural Phenomena · doi:10.1051/mmnp/20094302 · Cited by 39
“But cancer cells may avoid recognition by immune cells by fostering, through genome instability and facilities to develop adapted mutant cells, the outgrowth of low immunogenic tumour cell clones that escape immunosurveillance [280].”
BackgroundAnticancer Peptides and Proteins: A Panoramic View
Libério, M. S., Joanitti, G. A., Fontes, W., & Castro, M. S. (2013) · Protein and Peptide Letters · doi:10.2174/092986613805290435 · Cited by 38
Kraśko, J. A., Žilionytė, K., Darinskas, A., Strioga, M. M., Rjabceva, S. N., Zalutsky, I. V., Derevyanko, M., KULCHITSKY, V. A., Lubitz, W., Kudela, P., et al. (2016) · Oncology Reports · doi:10.3892/or.2016.5252 · Cited by 37
Lipoxidation and cancer immunity
Martín‐Sierra, C., Laranjeira, P., Domingues, M. R., & Paiva, A. A. (2019) · Redox Biology · doi:10.1016/j.redox.2019.101103 · Cited by 45
“Clinically manifest neoplasms can develop when tumour cells are able to escape immunosurveillance [129,130].”
BackgroundAdipocytes: A Novel Target for IL-15/IL-15Rα Cancer Gene Therapy
Xiao, R., Mansour, A. G., Huang, W., Chrislip, L. A., Wilkins, R. K., Queen, N. J., Youssef, Y., Mao, H. C., Caligiuri, M. A., & Cao, L. (2019) · Molecular Therapy · doi:10.1016/j.ymthe.2019.02.011 · Cited by 40
“INTRODUCTION Natural killer (NK) cells are part of the innate immune system and play an essential role in cancer immune surveillance by killing malignant cells and suppressing tumor growth.(1,2) NK cells are dependent on the presence of the cytokine interleukin (IL)-15, which supports their development and triggers th…”
Touitou, V., Daussy, C., Bodaghi, B., Camelo, S., de Kozak, Y., LeHoang, P., Naud, M., Varin, A., Thillaye-Goldenberg, B., Merle‐Béral, H., et al. (2007) · Investigative Ophthalmology & Visual Science · doi:10.1167/iovs.07-0008 · Cited by 37
Aptamers for CD Antigens: From Cell Profiling to Activity Modulation
Nozari, A., & Berezovski, M. V. (2016) · Molecular Therapy — Nucleic Acids · doi:10.1016/j.omtn.2016.12.002 · Cited by 40
“However, cytokines not only participate in immune response activation but also play major roles in immune tolerance, and moreover, some have dual functionality.(52) Therefore, the ability to manipulate cytokine-induced responses could have a major impact, particularly on immune-related disorders, such as autoimmune di…”
BackgroundBiziota, E., Mavroeidis, L., Hatzimichael, E. C., & Pappas, P. (2016) · Cancer Letters · doi:10.1016/j.canlet.2016.12.018 · Cited by 39
Liu, C., Chu, X., Yan, M., Qi, J., Liu, H., Gao, F., Gao, R., Ma, G., & Ma, Y. (2018) · International Journal of Pharmaceutics · doi:10.1016/j.ijpharm.2018.10.054 · Cited by 35
Tran, A. P., Al-Radhawi, M. A., Kareva, I., Wu, J., Waxman, D. J., & Sontag, E. D. (2020) · Frontiers in Immunology · doi:10.3389/fimmu.2020.01376 · Cited by 41
“Other factors affecting immunogenicity include changes in MHC-1 molecules and tumor-specific antigens on the tumor cell surface [55], stress-induced expression of NK cell stimulatory ligands, and decreases in NK inhibitory ligands [56].”
BackgroundAvengers against cancer: A new era of nano-biomaterial-based therapeutics
Kumar, N., Fazal, S., Miyako, E., Matsumura, K., & Rajan, R. (2021) · Materials Today · doi:10.1016/j.mattod.2021.09.020 · Cited by 41
Klein, O., Davis, I. D., McArthur, G. A., Chen, L., Haydon, A. M., Parente, P., Dimopoulos, N., Jackson, H. M., Xiao, K., Maraskovsky, E., et al. (2015) · Cancer Immunology Immunotherapy · doi:10.1007/s00262-015-1656-x · Cited by 39
“Anti-tumour immune responses in patients with advanced melanoma are compromised by several immuneregulatory mechanisms [15].”
BackgroundRiond, J., Rodriguez, S., Nicolau-Travers, M.-L., Saati, T. A., & Gairin, J. E. (2009) · PubMed · Cited by 36
Andreuzzi, E., Fejza, A., Polano, M., Poletto, E., Camicia, L., Carobolante, G., Tarticchio, G., Todaro, F., Carlo, E. D., Scarpa, M., et al. (2022) · Journal of Experimental & Clinical Cancer Research · doi:10.1186/s13046-022-02271-y · Cited by 40
“On one side, it can suppress tumor growth by destroying cancer cells or inhibiting their outgrowth, a process that is known as cancer immunosurveillance [12], chiefly mediated by myeloid derived suppressor cells (MDSC) [13].”
BackgroundCellular therapy of cancer with natural killer cells—where do we stand?
Klingemann, H. (2013) · Cytotherapy · doi:10.1016/j.jcyt.2013.03.011 · Cited by 43
“011 patient’s own (autologous) cytotoxic cells, on the other hand, are generally dysfunctional and unable to form proper immunological synapses with the malignant clone (6,7).”
Leveraging immunotherapy for the treatment of gynecologic cancers in the era of precision medicine
Zamarin, D., & Jazaeri, A. A. (2016) · Gynecologic Oncology · doi:10.1016/j.ygyno.2015.12.030 · Cited by 39
“Activated T cells then migrate to tumors through the systemic vasculature by following a chemokine gradient [5, 6] and extravasate through a series of interaction with adhesion molecules in the tumor endothelium [7].”
BackgroundLiu, W., Guo, W., Shen, L., Chen, Z., Luo, Q., Luo, X., Feng, G., Shu, Y., Gu, Y., Xu, Q., et al. (2017) · Oncotarget · doi:10.18632/oncotarget.13812 · Cited by 35
Liu, Y., Hu, Y., Gu, F., Liang, J., Zeng, Y., Hong, X., Zhang, K., & Liu, L. (2017) · Oncotarget · doi:10.18632/oncotarget.18771 · Cited by 40
“It is reasonable that newly diagnosed advanced patients harbored ill immune status reflected by higher LDNs/HDNs ratio, because immunosuppressive microenvironment is established concomitantly with neoplasm development [25].”
BackgroundZhang, Y., Li, Y., Li, H., Chen, W., & Liu, W. (2018) · Biomedicine & Pharmacotherapy · doi:10.1016/j.biopha.2018.02.045 · Cited by 35
Picard, E., Godet, Y., Laheurte, C., Dosset, M., Galaine, J., Beziaud, L., Loyon, R., Boullerot, L., Joseph, E. L. M., Spehner, L., et al. (2018) · OncoImmunology · doi:10.1080/2162402x.2018.1527498 · Cited by 45
“Tumor-induced modifications of NK cell phenotype and function is a well-known mechanism contributing to the tumor escape.(31) Here we described three circulating NK cell subsets in NSCLC patients such as CD56 CD16, CD56 Figure 4.”
BackgroundThe Immune Microenvironment of Malignant Pleural Mesothelioma: A Literature Review
Désage, A.-L., Karpathiou, G., Peoc’h, M., & Froudarakis, M. E. (2021) · Cancers · doi:10.3390/cancers13133205 · Cited by 34
“Memory T-cells are responsible for secondary response: 1) central memory T-cells remain in lymphoid tissues and express CCR7 and CD45RO on their surface, and 2) memory T-cells in tissues lack of CCR7 expression and express CCR3, CCR5 and CD45RO on their surface [60].”
BackgroundVo, H. V. T., Nguyen, Y. T., Kim, N., & Lee, H. J. (2023) · International Journal of Molecular Sciences · doi:10.3390/ijms242317038 · Cited by 40
“This sequestration inhibits the mobility of these immune cells, leading to immunosuppression [113,114].”
BackgroundThe clinical significance of systemic inflammation score in esophageal squamous cell carcinoma
Han, L., Song, Q., Jia, Y., Chen, X., Wang, C., Chen, P., Min, R., & Cheng, Y. (2015) · Tumor Biology · doi:10.1007/s13277-015-4152-1 · Cited by 35
“Nowadays, cancer-related inflammation is proposed as the seventh hallmark of cancer, which could regulate carcinogenesis, progression, and metastasis of malignancies [19].”
BackgroundMatsushita, T., Takada, W., Igarashi, K., Naruchi, K., Miyoshi, R., García‐Martin, F., Amano, M., Hinou, H., & Nishimura, S. (2013) · Biochimica et Biophysica Acta (BBA) - General Subjects · doi:10.1016/j.bbagen.2013.11.009 · Cited by 35
“Given that the immunosurveillance by such anti-cancer autoantibodies can identify and destroy cancer precursor cells in most healthy cases [94–96], it is not surprising that we can observe significant differences in the serum level of such autoantibodies even in cases for healthy human controls.”
BackgroundContribution of the immune system to the chemotherapeutic response
McDonnell, A. M., Nowak, A. K., & Lake, R. (2011) · Seminars in Immunopathology · doi:10.1007/s00281-011-0246-z · Cited by 37
“Cancer is a cell-autonomous genetic disease that is principally driven by modifications in oncogenes and tumor suppressor genes, however, once initial genetic changes have taken place, development of invasive cancer requires tumor cells to escape immune control [1, 2].”
BackgroundFalco, G. D., Terlizzi, M., Sirignano, M., Commodo, M., D’Anna, A., Aquino, R. P., Pinto, A., & Sorrentino, R. (2017) · Scientific Reports · doi:10.1038/srep43016 · Cited by 38
Hogan, D. J., Zhu, J., Diago, O. R., Gammon, D., Haghighi, A., Lu, G., Das, A., Gruber, H. E., Jolly, D. J., & Ostertag, D. G. (2018) · Clinical Cancer Research · doi:10.1158/1078-0432.ccr-18-0619 · Cited by 35
Can Immunogenic Chemotherapies Relieve Cancer Cell Resistance to Immune Checkpoint Inhibitors?
Vargas, T. R., & Apétoh, L. (2019) · Frontiers in Immunology · doi:10.3389/fimmu.2019.01181 · Cited by 43
Wang, F., Pu, K., & Li, J. (2022) · Small Methods · doi:10.1002/smtd.202201083 · Cited by 34
Nuffel, A. M. T. V., Corthals, J., Neyns, B., Heirman, C., Thielemans, K., & Bonehill, A. (2010) · Methods in molecular biology · doi:10.1007/978-1-60761-657-3_27 · Cited by 37
Wang, L., Wang, W.-M., Hsu, S., Lin, S., & Shieh, C.-C. K. (2015) · The Journal of Rheumatology · doi:10.3899/jrheum.140770 · Cited by 33
Immunotherapy in Acute Myeloid Leukemia
Arpinati, M., & Curti, A. (2013) · Immunotherapy · doi:10.2217/imt.13.152 · Cited by 35
Harnessing the immune system in the battle against breast cancer
Nakasone, E. S., Hurvitz, S. A., & McCann, K. E. (2018) · Drugs in Context · doi:10.7573/dic.212520 · Cited by 35
“Preclinical animal studies in the 1960s and 1970s showed that administration of polyadenylic-polyuridylic acid (poly A:U), a double-stranded RNA polynucleotide that stimulates TLR3, after mastectomy in spontaneous tumor and orthotopic occurs through the selection and outgrowth of cancer cells with low immunogenicity a…”
BackgroundPositive & Negative Roles of Innate Effector Cells in Controlling Cancer Progression
Stolk, D. A., van der Vliet, H. J., de Gruijl, T. D., van Kooyk, Y., & Exley, M. A. (2018) · Frontiers in Immunology · doi:10.3389/fimmu.2018.01990 · Cited by 34
“Tumors can develop different strategies to evade NKmediated lysis (29) (Figure 1B).”
BackgroundFreund, E., & Bekeschus, S. (2020) · IEEE Transactions on Radiation and Plasma Medical Sciences · doi:10.1109/trpms.2020.3029982 · Cited by 33
Placke, T., Kopp, H., & Salih, H. R. (2012) · OncoImmunology · doi:10.4161/onci.19367 · Cited by 33
Immune Recruitment and Therapeutic Synergy: Keys to Optimizing Oncolytic Viral Therapy?
Naik, J., Twelves, C., Selby, P. J., Vile, R. G., & Chester, J. D. (2011) · Clinical Cancer Research · doi:10.1158/1078-0432.ccr-10-2848 · Cited by 33
“A comprehensive review of the immune system in the context of OV therapy is beyond the scope of this article and has been summarized elsewhere (42, 43).”
Leffers, N., Lambeck, A. J. A., de Graeff, P., Bijlsma, A. Y., Daemen, T., van der Zee, A. G. J., & Nijman, H. W. (2008) · Gynecologic Oncology · doi:10.1016/j.ygyno.2008.04.043 · Cited by 36
“tumour cells with less immunogenic characteristics have a survival benefit over tumour cells that are easily recognised by the immune system [16,17].”
BackgroundResultIelpo, S., Barberini, F., Moghaddam, F. D., Pesce, S., Cencioni, C., Spallotta, F., Ninno, A. D., Businaro, L., Marcenaro, E., Bei, R., et al. (2024) · Cancer Treatment Reviews · doi:10.1016/j.ctrv.2024.102843 · Cited by 36
Immune adjuvants as critical guides directing immunity triggered by therapeutic cancer vaccines
Schijns, V. E. C. J., Tartour, É., Michálek, J., Stathopoulos, A., Dobrovolskienė, N., & Strioga, M. M. (2013) · Cytotherapy · doi:10.1016/j.jcyt.2013.09.008 · Cited by 35
Zhu, J., Lou, Y., Liu, P., & Xu, L. X. (2020) · International Journal of Hyperthermia · doi:10.1080/02656736.2020.1788173 · Cited by 34
“[4] Zitvogel L, Tesniere A, Kroemer G.”
Current and future biomarkers for outcomes with immunotherapy in non-small cell lung cancer
Duchemann, B., Remón, J., Naigeon, M., Cassard, L., Jouniaux, J.-M., Boselli, L., Grivel, J., Auclin, É., Desnoyer, A., Besse, B., et al. (2021) · Translational Lung Cancer Research · doi:10.21037/tlcr-20-839 · Cited by 35
“This microenvironment is constantly evolving, dependent on signaling molecules, with the cancer cells promoting immune evasion on the one hand and the host controlling tumoral proliferation on the other (68,69).”
BackgroundSynthetic induction of immunogenic cell death by genetic stimulation of endoplasmic reticulum stress
Michaud, M., Sukkurwala, A. Q., Sano, F. D., Zitvogel, L., Kepp, O., & Kroemer, G. (2014) · OncoImmunology · doi:10.4161/onci.28276 · Cited by 36
“There are multiple pathways through which antineoplastic agents can stimulate anticancer immune responses.(4,5) On one hand, chemotherapeutics can act on immune cells by stimulating effector mechanisms, for instance by activating dendritic cells (DCs) and cytotoxic T lymphocytes (CTLs).”
Holdenrieder, S., Eichhorn, P., Beuers, U. H., Samtleben, W., Stieber, P., Nagel, D., Peterfi, A., Steinle, A., & Salih, H. R. (2007) · PubMed · Cited by 33
Ai, R., Yan, T., Hao, Y., Jiang, L., Dan, H., Ji, N., Zeng, X. Y., Zhou, Y. J., & Chen, Q. (2017) · Oncotarget · doi:10.18632/oncotarget.20312 · Cited by 37
“In the early phase, the immune system can eliminate the damaged cells [98].”
BackgroundNanomedicine-induced programmed cell death enhances tumor immunotherapy
Lu, J., Tai, Z., Wu, J., Li, L., Zhang, T., Liu, J., Zhu, Q., & Chen, Z. (2023) · Journal of Advanced Research · doi:10.1016/j.jare.2023.09.018 · Cited by 34
Cancer treatment and the KIR–HLA system: an overview
Leone, P., Re, V. D., Vacca, A., Dammacco, F., & Racanelli, V. (2017) · Clinical and Experimental Medicine · doi:10.1007/s10238-017-0455-4 · Cited by 33
Jacquelot, N., Pitt, J. M., Enot, D. P., Roberti, M. P., Duong, C. P. M., Rusakiewicz, S., Eggermont, A. M. M., & Zitvogel, L. (2017) · OncoImmunology · doi:10.1080/2162402x.2017.1299303 · Cited by 30
“From immunosurveillance through to immunoediting, tumor-infiltrating immune cells play a central role in cancer progression and, accordingly, can make excellent prognostic markers.(2) The study of immune infiltrates in several pathologies,(3) including ovarian cancer,(4) gastrointestinal tumors(5) and colon carcinoma(…”
BackgroundImmune Checkpoint Blockade in Breast Cancer Therapy
Bu, X., Yao, Y., & Li, X. (2017) · Advances in experimental medicine and biology · doi:10.1007/978-981-10-6020-5_18 · Cited by 36
Pereira, M. B., Barros, L. R. C., Bracco, P. A., Vigo, Á., Boroni, M., Bonamino, M., & Lenz, G. (2018) · OncoImmunology · doi:10.1080/2162402x.2018.1431083 · Cited by 38
Sebastian, S., & Neilaj, S. (2019) · Therapeutic Advances in Gastroenterology · doi:10.1177/1756284818817293 · Cited by 31
Immunology of Aging and Cancer Development
Fülöp, T., Larbi, A., Kotb, R. R., & Pawelec, G. (2013) · Interdisciplinary topics in gerontology and geriatrics · doi:10.1159/000343599 · Cited by 31
Xiang, Y., Guo, M.-M., Zhou, C., Liu, L., Han, B., Kong, L., Gao, Z., Ma, Z., Wang, L., Feng, M., et al. (2014) · PLoS ONE · doi:10.1371/journal.pone.0109449 · Cited by 31
“Tumor immunosurveillance is known to be of critical importance in controlling tumorigenesis and progression in various cancers [18,19,20].”
BackgroundZitvogel, L., Kepp, O., Aymeric, L., Ma, Y., Locher, C., Delahaye, N. F., André, F., & Kroemer, G. (2010) · Cancer Research · doi:10.1158/0008-5472.can-10-1003 · Cited by 31
“During the oncogenic process, dedifferentiation can induce (a) overexpression of tumor-associated antigens or neomutations that elicit specific T-cell responses, (b) exposure of stress-induced danger signals (such as ligands of the NK receptor NKG2D) that elicit anticancer immunosurveillance through critical receptors…”
BackgroundLim, K. H. J., Telisinghe, P. U., Abdullah, M. S., & Ramasamy, R. (2010) · PubMed · Cited by 30
Dopamine inhibits human CD8+ Treg function through D1-like dopaminergic receptors
Nasi, G., Ahmed, T., Rasini, E., Fenoglio, D., Marino, F., Filaci, G., & Cosentino, M. (2019) · Journal of Neuroimmunology · doi:10.1016/j.jneuroim.2019.02.007 · Cited by 32
Cândido, E. B., Silva, L. M., Teixeira‐Carvalho, A., Lamaita, R. M., Filho, R. M. P., Cota, B. D. C. V., & Filho, A. L. D. S. (2012) · Reproductive Sciences · doi:10.1177/1933719112466299 · Cited by 33
“Epithelial ovarian cancer is an immunogenic tumor, as indicated by the presence of tumor-infiltrating lymphocytes (TILs), which creates an immune suppressive microenvironment in order to escape from the immune elimination.3 Immune response is characterized by the division of CD4þ T-helper (Th) cells into 2 functional…”
BackgroundInfluentialBrain cancer immunoediting: novel examples provided by immunotherapy of malignant gliomas
Pellegatta, S., Cuppini, L., & Finocchiaro, G. (2011) · Expert Review of Anticancer Therapy · doi:10.1586/era.11.102 · Cited by 31
Coevolution of Leukemia and Host Immune Cells in Chronic Lymphocytic Leukemia
Purroy, N., & Wu, C. J. (2017) · Cold Spring Harbor Perspectives in Medicine · doi:10.1101/cshperspect.a026740 · Cited by 33
“In turn, to subvert these physiological immune responses, tumor cells can either generate an immunosuppressive environment or escape from immune recognition (reviewed in Dunn et al. 2002, 2004; Zitvogel et al. 2006).”
BackgroundPresent and Future of Immunotherapy for Triple-Negative Breast Cancer
Sriramulu, S., Thoidingjam, S., Speers, C. W., & Nyati, S. (2024) · Cancers · doi:10.3390/cancers16193250 · Cited by 34
“Additionally, by releasing MHC molecules and cell surface antigens, chemotherapy drugs improve the immunogenicity of tumors [126].”
BackgroundNovel immunotherapy in the treatment of advanced non-small cell lung cancer
Santabarbara, G., Maione, P., Rossi, A., Palazzolo, G., & Gridelli, C. (2016) · Expert Review of Clinical Pharmacology · doi:10.1080/17512433.2016.1236681 · Cited by 31
“role in control cancer identifying and destroying foreign or abnormal cells [11,12].”
BackgroundHamilton, D. H., David, J. M., Dominguez, C. L., & Palena, C. (2017) · Cells Tissues Organs · doi:10.1159/000446495 · Cited by 29
Atezolizumab for the treatment of breast cancer
Basile, D., Pelizzari, G., Vitale, M. G., Lisanti, C., Cinausero, M., Iacono, D., & Puglisi, F. (2018) · Expert Opinion on Biological Therapy · doi:10.1080/14712598.2018.1469619 · Cited by 30
“9% Pembrolizumab [13] II PD-1 TNBC, PD-L1+, I Line 52 ORR 23.”
BackgroundInfluentialImmunosenescence is a therapeutic target for frailty in older adults: a narrative review
Jia, H., Huang, W., Liu, C., Tang, S., Zhang, J., Chen, C., Tian, Y., & Zhong, W. (2022) · Annals of Translational Medicine · doi:10.21037/atm-22-4405 · Cited by 33
“The immune system may be responsible for recognizing and eliminating cancer precursors (38), mainly regulated by cytotoxic natural killer NK and CD8 T cells.”
BackgroundSimple biophysical model of tumor evasion from immune system control
d’Onofrio, A., & Ciancio, A. (2011) · Physical Review E · doi:10.1103/physreve.84.031910 · Cited by 29
Recurrence‐free survival in prostate cancer is related to increased stromal TRAIL expression
Anees, M., Horak, P., El‐Gazzar, A., Susani, M., Heinze, G., Perco, P., Loda, M. F., Lis, R. T., Krainer, M., & Oh, W. K. (2010) · Cancer · doi:10.1002/cncr.25504 · Cited by 30
“adaptive immune responses through various escape mechanisms.(19) In terms of TRAIL resistance, these include mutation or downregulation of death receptors, methylation of caspase-8 encoding genes, and overexpression of FLIP, thus potentially disabling immunosurveillance regulating mechanisms by host cytotoxic T cells.”
BackgroundOhtake, J., Ohkuri, T., Togashi, Y., Kitamura, H., Okuno, K., & Nishimura, T. (2014) · Immunology Letters · doi:10.1016/j.imlet.2014.04.010 · Cited by 29
Aging, cancer, and cancer vaccines
Mazzola, P., Radhi, S., Mirandola, L., Annoni, G., Jenkins, M., Cobos, E., & Chiriva‐Internati, M. (2012) · Immunity & Ageing · doi:10.1186/1742-4933-9-4 · Cited by 30
“They are largely represented by clonally expanded populations reactive towards cytomegalovirus (CMV) and Epstein-Barr virus (EBV) determinants [24].”
BackgroundInfluentialPotential immunotherapy targets in recurrent cervical cancer
Ring, K. L., Yemelyanova, A. V., Soliman, P. T., Frumovitz, M. M., & Jazaeri, A. A. (2017) · Gynecologic Oncology · doi:10.1016/j.ygyno.2017.02.027 · Cited by 31
Stricker, T. P., & KUMAR, V. (2010) · Elsevier eBooks · doi:10.1016/b978-1-4377-0792-2.50012-2 · Cited by 60
Immunogenic chemotherapy: discovery of a critical protein through proteomic analyses of tumor cells.
Apétoh, L., Obéid, M., Tesnière, A., Ghiringhelli, F., Fimia, G. M., Piacentini, M., Kroemer, G., & Zitvogel, L. (2007) · PubMed · Cited by 41
Immune checkpoint blockade therapy for bladder cancer treatment
Kim, J. (2016) · Korean journal of urology · doi:10.4111/icu.2016.57.s1.s98 · Cited by 30
“Cancer immuno-surveillance and immuno-editing have been proposed as mechanisms by which tumors escape control through the development of tumor immunogenicity by the body’s own immune system [15,18].”
BackgroundTumour escape mechanisms and their therapeutic implications in combination tumour therapy
Bhutia, S. K., Mallick, S. K., & Maiti, T. K. (2010) · Cell Biology International · doi:10.1042/cbi20090206 · Cited by 33
“At the same time, the tumour cells seek assistance of other immune cells, such as Treg cells (regulatory T-cells), MSCs (myeloid suppressor cells), NKT cells (natural killer T cells) and immunosuppressive DCs (dendrite cells) (Piemonti et al., 2003; Zitvogel et al., 2006).”
BackgroundIFN-γ and tumor gangliosides: Implications for the tumor microenvironment
Dillinger, B., Ahmadi-Erber, S. M., Lau, M., Hölzl, M. A., Erhart, F., Juergens, B., Fuchs, D., Heitger, A., Ladisch, S., & Dohnal, A. M. (2018) · Cellular Immunology · doi:10.1016/j.cellimm.2018.01.014 · Cited by 33
“Current concepts of tumor development hold that tumor cell growth is subject to surveillance by the immune system [1], which recognizes and eliminates aberrant tumor cells [2].”
BackgroundAhn, R., & Ursini‐Siegel, J. (2021) · International Journal of Molecular Sciences · doi:10.3390/ijms22052608 · Cited by 31
Chauhan, S., Jaiswal, S., Jakhmola, V., Singh, B. P., Bhattacharya, S., Garg, M., & Sengupta, S. (2024) · Cancer Letters · doi:10.1016/j.canlet.2024.216766 · Cited by 32
Evolving models of tumor origin and progression
Mitrus, I., Bryndza, E., Sochanik, A., & Szala, S. (2012) · Tumor Biology · doi:10.1007/s13277-012-0389-0 · Cited by 45
“At later stages, cancer cells not only avoid immune recognition, but they also produce cytokines and chemokines via which they carry a specific “talk” with cells forming tumor milieu [38].”
BackgroundBuechele, C., Baessler, T., Schmiedel, B. J., Schumacher, C. E., Große‐Hovest, L., Rittig, K., & Salih, H. R. (2011) · European Journal of Immunology · doi:10.1002/eji.201141920 · Cited by 28
Cello (2010) · International Journal of Oncology · doi:10.3892/ijo_00000826 · Cited by 30
Basa, R. C. B., Davies, V., Li, X., Murali, B., Shah, J., Yang, B., Shi, L., Khan, M. W., Tian, M., Tejada, R., et al. (2016) · PLoS ONE · doi:10.1371/journal.pone.0156660 · Cited by 30
“One challenge the immune system has is the strong immunosuppressive qualities of the tumor microenvironment that limit the potential of immunity in interceding efficiently [8, 9].”
BackgroundLiou, A. K. F., Soon, G. S. T., Tan, L. S. Y., Yang, P., Cher, B. M., Goh, B. C., Wang, S., & Lim, C. M. (2020) · Oral Oncology · doi:10.1016/j.oraloncology.2020.104616 · Cited by 28
Piconese, S., & Colombo, M. P. (2007) · Springer eBooks · doi:10.1007/978-0-387-69118-3_4 · Cited by 29
“immune players (Zitvogel et al., 2006).”
Coinhibitory molecules in cancer biology and therapy
Mocellin, S., Benna, C., & Pilati, P. (2013) · Cytokine & Growth Factor Reviews · doi:10.1016/j.cytogfr.2013.01.003 · Cited by 28
“Despite these observations, it is evident that malignant cells represent elusive targets for the immune system [5,6].”
BackgroundInterleukin-32: Frenemy in cancer?
Han, S., & Yang, Y. D. (2019) · BMB Reports · doi:10.5483/bmbrep.2019.52.3.019 · Cited by 29
Nguyen, R., Bae, S. D. W., Zhou, G., Read, S. A., Ahlenstiel, G., George, J., & Qiao, L. (2020) · Biochimica et Biophysica Acta (BBA) - Reviews on Cancer · doi:10.1016/j.bbcan.2020.188350 · Cited by 28
Wu, S., Xie, S.-A., Yuan, C., Yang, Z., Liu, S., Zhang, Q., Sun, F., Wu, J., Zhan, S., Zhu, S., et al. (2022) · Inflammatory Bowel Diseases · doi:10.1093/ibd/izac096 · Cited by 28
Santangelo, M. L., Criscitiello, C., Renda, A., Federico, S., Curigliano, G., Dodaro, C. A., Scotti, A., Tammaro, V., Calogero, A., Riccio, E., et al. (2015) · BioMed Research International · doi:10.1155/2015/183523 · Cited by 27
“Over the past decades, a growing body of evidence has emerged demonstrating the dual role of the immune system in cancer, being involved both in tumor development (via chronic inflammation through the innate immune system) and in tumor elimination and control (through the adaptive immune system) [3].”
BackgroundStathopoulos, A., Pretto, C. M., Devillers, L., Denis, P., Hofman, F. M., Kruse, C. A., Jadus, M. R., Chen, T. C., & Schijns, V. E. C. J. (2012) · OncoImmunology · doi:10.4161/onci.19068 · Cited by 31
“In recent years it has become well-established that many tumors, including GBM, use various mechanisms of immune suppression or evasion, including immunediting, and the generation of T regulatory (Treg) and myeloid derived suppressor cells (MDSC).(12) These cells act to inhibit the beneficial effects of immune activat…”
BackgroundTumour‐specific induction of immune complexes: DCP‐IgM in hepatocellular carcinoma
Beneduce, L., Pesce, G., Gallotta, A., Zampieri, F., Biasiolo, A., Tono, N., Boscato, N., Gatta, A., Pontisso, P., & Fassina, G. (2008) · European Journal of Clinical Investigation · doi:10.1111/j.1365-2362.2008.01985.x · Cited by 27
Oncogene withdrawal engages the immune system to induce sustained cancer regression
Casey, S. C., Li, Y., Fan, A. C., & Felsher, D. W. (2014) · Journal for ImmunoTherapy of Cancer · doi:10.1186/2051-1426-2-24 · Cited by 30
“Thus, immune surveillance mechanisms are critical both to the prevention as well the efficacy of conventional treatment of these cancers [57-59] and are a critical component to the therapeutic efficacy of agents for cancer [54,60-62].”
BackgroundKlepsch, V., Hermann‐Kleiter, N., & Baier, G. (2016) · Immunology Letters · doi:10.1016/j.imlet.2016.03.007 · Cited by 29
“Consistently, the immune system of transplant patients who receive immunosuppressive drugs is less able to detect and destroy cancer cells [2].”
BackgroundInfluentialPeptide-Based Cancer Vaccine Strategies and Clinical Results
Schneble, E. J., Clifton, G. T., Hale, D. F., & Peoples, G. E. (2016) · Methods in molecular biology · doi:10.1007/978-1-4939-3387-7_46 · Cited by 27
Bonmort, M., Ullrich, E., Mignot, G., Jacobs, B., Chaput, N., & Zitvogel, L. (2007) · Biochimie · doi:10.1016/j.biochi.2007.04.014 · Cited by 29
Immunotherapy in OSCC: Current trend and challenges
Gupta, S., Singh, A., Deorah, D. S., & Tomar, A. (2025) · Critical Reviews in Oncology/Hematology · doi:10.1016/j.critrevonc.2025.104672 · Cited by 30
Colorectal cancer vaccines in clinical trials
Speetjens, F. M., Zeestraten, E. C. M., Kuppen, P. J. K., Melief, C. J. M., & van der Burg, S. H. (2011) · Expert Review of Vaccines · doi:10.1586/erv.11.63 · Cited by 28
Immune Checkpoint Inhibitors in the Cancer Patient with An Organ Transplant
Wanchoo, R., Riella, L. V., Uppal, N. N., Lopez, C. A., Nair, V. V., Devoe, C., & Jhaveri, K. D. (2017) · Journal of Onco-Nephrology · doi:10.5301/jo-n.5000006 · Cited by 28
“However, tumors escape this process by employing mechanisms to avoid recognition by the immune system or actively suppress anticancer immune responses (3, 4).”
BackgroundA gene signature for immune subtyping of desert, excluded, and inflamed ovarian tumors
Mlynska, A., Vaišnorė, R., Rafanavičius, V., Jocys, S., Janeiko, J., Petrauskytė, M., Bijeikis, S., Cimmperman, P., Intaitė, B., Žilionytė, K., et al. (2020) · American Journal of Reproductive Immunology · doi:10.1111/aji.13244 · Cited by 27
Caregivers with Cancer Patients: Focus on Hispanics
Bisht, J., Rawat, P., Sehar, U., & Reddy, P. H. (2023) · Cancers · doi:10.3390/cancers15030626 · Cited by 28
“without a signal, invade the tissues, and disseminate to other parts of the body [6].”
BackgroundInfluential
Metadata
- Authors
- Zitvogel, L., Tesniere, A., & Kroemer, G.
- Affiliations
- Inserm (FR)
- Centre National de la Recherche Scientifique (FR)
- Corresponding author
- Kroemer, Guido
- Venue
- Nature reviews. Immunology
- Published
- 2006-09-15
- Volume
- 6
- Issue
- 10
- Pages
- 715-727
- ISSN
- 1474-1733 (ISSN-L)
- 1474-1741
- OpenAlex
- W2063192133
- Cited by
- 1,324
- References
- 127
- Citations by year
- 2026: 15 · 2025: 26 · 2024: 62 · 2023: 75 · 2022: 68 · 2021: 63 · 2020: 63 · 2019: 60 · 2018: 66 · 2017: 76 · 2016: 72 · 2015: 81 · 2014: 87 · 2013: 89 · 2012: 82
- FWCI
- 5.85
- Type
- journal article
- Language
- en
- Open access
- closed
- Licence
- www.springernature.com/gp/researchers/text-and-data-mining (tdm)
- www.springernature.com/gp/researchers/text-and-data-mining (vor)
- Locations
- Nature reviews. Immunology (publishedVersion)
- PubMed (publishedVersion)
- Funders
- European Commission
- Conseil Régional, Île-de-France
- Institut National Du Cancer
- Cancéropôle Ile de France
- Topics
- Health Sciences › Medicine › Oncology › Cancer Immunotherapy and Biomarkers
- Life Sciences › Immunology and Microbiology › Immunology › Immunotherapy and Immune Responses
- Life Sciences › Immunology and Microbiology › Immunology › T-cell and B-cell Immunology
- Keywords
- tumor surveillance, immunoselection, tumor immunogenicity, antitumor immunity, carcinogenesis, immunogenic chemotherapy
- MeSH terms
- Animals, Humans, Immune Tolerance, Immunologic Surveillance, Neoplasms, T-Lymphocytes, Signal Transduction
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.